GEN Exclusives

More »

GEN News Highlights

Back to Item »

BioMS Stock Free-Falls as Late-Stage Development of Sole Clinical Candidate Gets the Axe

Dirucotide did not meet endpoints in one of three Phase III studies in secondary progressive multiple sclerosis.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »